A randomised, phase III study(OPTIMAL, CTONG-0802) [31] comparing erlotinib with chemotherapy as first-line treatment of EGFR mutation-positive advanced NSCLC showed erlotinib should be considered standard first-line treatment of patients with advanced NSCLC and EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.